Charles Shapiro
Medical Oncology · New York, NYNPI 1972511103
Payments from drug & device makers
$904,699in general payments, 2019–2025
Across 30 payments — averaging $30,157 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$892K
- Genentech, Inc.$12K
- Gilead$652
- Lilly USA, LLC$48
What the payments were for
- Consulting fees$64051%
- Speaking & faculty fees$55044%
- Food & beverage$484%
- Education$121%
General payments by program year
21
22
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 23 | $891,695 |
| Genentech, Inc. | 2 | $12,304 |
| Gilead | 3 | $652 |
| Lilly USA, LLC | 2 | $48 |
How this compares
$904,699 in reported general payments places this provider in the 65th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.